25K Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Karyopharm Therapeutics Inc

Watchlist Manager

Watchlist

Price: 4.7 EUR -1.67%

Market Cap: €547.3m

K	Karyopharm Therapeutics Inc F:25K	US
K	Kaspi.kz AO NASDAQ:KSPI	KZ
	Heartbeam Inc NASDAQ:BEAT	US

Profitability Summary

Karyopharm Therapeutics Inc's profitability score is 30/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

96%

Strong 3Y Average Gross Margin

96%

Declining Gross Margin

96% > 96%

Negative Operating Margin

-97%

Negative 3Y Average Operating Margin

-82%

Declining Operating Margin

-86% > -97%

Negative Net Margin

-129%

Negative 3Y Average Net Margin

-88%

Declining Net Margin

-97% > -129%

Negative Free Cash Flow Margin

-39%

Negative 3Y Average Free Cash Flow Margin

-72%

Free Cash Flow Margin is Increasing

-68% > -39%

Exceptional ROE

83%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-218%

Declining ROIC

-176% > -332%

View All

Hide

Collapse

30 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.